within Pharmacolibrary.Drugs.ATC.N;

model N04BD01
  extends Pharmacokinetic.Models.PK_2C_enteral(
    weight         = 70,
    F              = 0.04,
    Cl             = 0.0035,
    adminDuration  = 600,
    adminMass      = 10 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.16,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.0023000000000000004,
    Tlag           = 600,            
    Vdp             = 0.23,
    k12             = 74,
    k21             = 74
    
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>N04BD01</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>2</td></tr></table><p>Selegiline is a selective, irreversible monoamine oxidase B (MAO-B) inhibitor used primarily as an adjunct in the treatment of Parkinson's disease and sometimes in the treatment of major depressive disorder. It works by increasing dopaminergic activity in the brain. Selegiline is an approved medication widely used in clinical practice.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters are reported in healthy adult volunteers following oral administration.</p><h4>References</h4><ol><li><p>Chen, L, et al., &amp; Xiang, P (2019). Pharmacokinetics of selegiline, R-methamphetamine, R-amphetamine, and desmethylselegiline in oral fluid after a single oral administration of selegiline. <i>Drug testing and analysis</i> 11(6) 898–905. DOI:<a href=&quot;https://doi.org/10.1002/dta.2568&quot;>10.1002/dta.2568</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/30614204/&quot;>https://pubmed.ncbi.nlm.nih.gov/30614204</a></p></li><li><p>Laine, K, et al., &amp; Huupponen, R (1999). Dose linearity study of selegiline pharmacokinetics after oral administration: evidence for strong drug interaction with female sex steroids. <i>British journal of clinical pharmacology</i> 47(3) 249–254. DOI:<a href=&quot;https://doi.org/10.1046/j.1365-2125.1999.00891.x&quot;>10.1046/j.1365-2125.1999.00891.x</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/10215747/&quot;>https://pubmed.ncbi.nlm.nih.gov/10215747</a></p></li><li><p>Mahmood, I (1997). Clinical pharmacokinetics and pharmacodynamics of selegiline. An update. <i>Clinical pharmacokinetics</i> 33(2) 91–102. DOI:<a href=&quot;https://doi.org/10.2165/00003088-199733020-00002&quot;>10.2165/00003088-199733020-00002</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/9260033/&quot;>https://pubmed.ncbi.nlm.nih.gov/9260033</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end N04BD01;
